Webinar: Advocates’ Debrief on the Science of Daily F/TAF vs TDF/FTC as PrEP

This webinar was the first in a two-part series, responding to advocates’ desire to better understand the research to date on F/TAF as PrEP, especially as it related to its safety profile v/ TDF/FTC and lack of robust data in cisgender women. This issue came into greater focus during an August 7 FDA advisory committee meeting at which Gilead’s regulatory submission of F/TAF for PrEP was discussed and debated. On the webinar, we were joined by researchers Andrew Hill (senior visiting Research Fellow in the Pharmacology Department at Liverpool University) and Monica Gandhi (Professor of Medicine and Associate Division Chief of the Division of HIV, Infectious Diseases, and Global Medicine at UCSF/ San Francisco General Hospital) who shared their take on the latest research and helped unpack the details of the August 7 discussion to inform an advocacy agenda on what should happen next.